Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation filings document a biotechnology royalty aggregator with Nasdaq-listed common stock, Series A cumulative perpetual preferred stock, and Series B depositary shares. Form 8-K reports cover operating results, Regulation FD presentations, material definitive agreements, completed acquisition activity, and officer appointments tied to the company’s royalty aggregation strategy.
Proxy materials describe annual meeting procedures, board and stockholder voting matters, and governance disclosures. The filing record also documents the company’s capital structure, including preferred stock classes, and formal disclosures around completed acquisitions and related legacy asset information.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.
XOMA Royalty Corporation and its subsidiary XRA 7 Corp. have filed Amendment No. 2 to their tender offer for all outstanding shares of Generation Bio Co. at $4.2913 in cash plus one contingent value right (CVR) per share. Each CVR may entitle holders to future cash payments if specified events occur under a CVR Agreement. The Buyer Entities state they did not obtain an independent valuation or material non-public analysis of potential CVR proceeds and are relying on Generation Bio’s own estimate. They emphasize that they cannot predict whether any CVR proceeds will ever be paid, or in what amount or timing. The amendment explains that any Net Cash Shortfall can only be recovered from CVR proceeds that would otherwise become payable, and CVR holders will only learn of such a shortfall if it reduces a payment. It also confirms that all offer conditions are for the Buyer Entities’ benefit, that the minimum tender and termination conditions cannot be waived, and that if any condition is triggered the Buyer Entities will promptly inform stockholders whether they intend to assert or waive it.
XOMA Royalty Corporation and its subsidiary XRA 7 Corp. have filed Amendment No. 2 to their tender offer for all outstanding shares of Generation Bio Co. at $4.2913 in cash plus one contingent value right (CVR) per share. Each CVR may entitle holders to future cash payments if specified events occur under a CVR Agreement. The Buyer Entities state they did not obtain an independent valuation or material non-public analysis of potential CVR proceeds and are relying on Generation Bio’s own estimate. They emphasize that they cannot predict whether any CVR proceeds will ever be paid, or in what amount or timing. The amendment explains that any Net Cash Shortfall can only be recovered from CVR proceeds that would otherwise become payable, and CVR holders will only learn of such a shortfall if it reduces a payment. It also confirms that all offer conditions are for the Buyer Entities’ benefit, that the minimum tender and termination conditions cannot be waived, and that if any condition is triggered the Buyer Entities will promptly inform stockholders whether they intend to assert or waive it.
XOMA Royalty Corporation is making a leadership change in its finance organization. Effective January 12, 2026, the board appointed Jeffrey Trigilio as Chief Financial Officer, succeeding Thomas Burns, who stepped down from his role on the same date.
Mr. Trigilio will receive an annual base salary of $515,000 and is eligible for a target annual cash bonus equal to 40% of base salary. His compensation package includes an initial grant of 30,000 performance units that vest based on stock price hurdles over a period ending on the earlier of May 18, 2026 or the 2026 annual stockholder meeting, plus a 2026 annual equity grant valued at 180,000 times the closing price of XOMA common stock on the effective date.
The employment agreement provides severance and change-of-control protections, including up to 1.5 times base salary and target bonus, extended health benefits, outplacement services, and accelerated equity vesting in certain termination scenarios. Mr. Burns will receive severance under his existing agreement, acceleration of certain performance stock units, and a consulting role for three months at $16,000 per month to support transition.
XOMA Royalty Corp reported an equity award to its Chief Financial Officer, Jeffrey Trigilio. On 01/12/2026, he was granted 30,000 Performance Stock Units (PSUs) at an exercise price of $0 per unit, recorded as a derivative security held directly.
Each PSU represents a contingent right to receive one share of XOMA common stock. The PSUs vest only if XOMA’s common stock reaches a specified price per share, tying the potential stock delivery to future share-price performance. After this grant, Trigilio beneficially owned 30,000 PSUs.
XOMA Royalty Corp filed an initial insider ownership report for Chief Financial Officer Jeffrey Trigilio. The Form 3 indicates that, at the time of this filing, no securities of XOMA Royalty Corp are beneficially owned. The form is filed by one reporting person, reflecting his role as an officer and providing a baseline disclosure of his current holdings status.
XOMA Royalty Corporation, through its subsidiary XRA 7 Corp., is conducting a tender offer to acquire all outstanding shares of Generation Bio Co. (GBIO) common stock. Each share is being offered $4.2913 in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (CVR) that may provide additional cash payments under a CVR agreement.
This amendment updates only the timing of the offer. The expiration has been changed from one minute after 11:59 p.m. Eastern Time on February 8, 2026 to one minute after 11:59 p.m. Eastern Time on February 6, 2026. All other terms and conditions of the tender offer remain the same as previously described in the offer materials.
XOMA Royalty Corporation, through its subsidiary XRA 7 Corp., is conducting a tender offer to acquire all outstanding shares of Generation Bio Co. (GBIO) common stock. Each share is being offered $4.2913 in cash, without interest and less any applicable tax withholding, plus one non-tradable contingent value right (CVR) that may provide additional cash payments under a CVR agreement.
This amendment updates only the timing of the offer. The expiration has been changed from one minute after 11:59 p.m. Eastern Time on February 8, 2026 to one minute after 11:59 p.m. Eastern Time on February 6, 2026. All other terms and conditions of the tender offer remain the same as previously described in the offer materials.
XOMA Royalty Corporation filed a current report to let investors know it has made an updated corporate presentation available as of January 12, 2026. The presentation is attached as Exhibit 99.1 and is intended to provide refreshed information about the company.
The company specifies that the material in Item 7.01, including the presentation, is being furnished rather than filed, meaning it is not subject to certain Exchange Act liability provisions and is not automatically incorporated into other SEC filings unless specifically referenced.
XOMA Royalty Corporation and its wholly owned subsidiary XRA 7 Corp. plan to launch a cash tender offer to acquire all issued and outstanding shares of common stock of Generation Bio Co. under an Agreement and Plan of Merger dated December 15, 2025. The communication explains that the offer has not yet commenced and that full terms will be provided in formal tender offer materials on Schedule TO and a related Schedule 14D-9 recommendation statement to be filed with the SEC.
It also contains extensive forward-looking statements and risk disclosures, noting that the transactions may be delayed or may not close due to factors such as competing offers, the level of stockholder tenders, legal proceedings, failure to satisfy closing conditions, possible termination of the merger agreement and uncertainty around any contingent value rights payments to Generation Bio stockholders.
XOMA Royalty Corporation and its wholly owned subsidiary XRA 7 Corp. plan to launch a cash tender offer to acquire all issued and outstanding shares of common stock of Generation Bio Co. under an Agreement and Plan of Merger dated December 15, 2025. The communication explains that the offer has not yet commenced and that full terms will be provided in formal tender offer materials on Schedule TO and a related Schedule 14D-9 recommendation statement to be filed with the SEC.
It also contains extensive forward-looking statements and risk disclosures, noting that the transactions may be delayed or may not close due to factors such as competing offers, the level of stockholder tenders, legal proceedings, failure to satisfy closing conditions, possible termination of the merger agreement and uncertainty around any contingent value rights payments to Generation Bio stockholders.
Owen Hughes, Chief Executive Officer and director of XOMA Royalty Corp, reported acquiring 100,000 depositary shares of the company’s 8.375% Series B cumulative preferred stock on 12/04/2025 at $25.05 per share. After this transaction, he beneficially owns 102,000 of these depositary shares directly, along with 98,268 common shares held directly and 295 common shares held through a 401(k) plan.
XOMA Royalty Corporation completed its acquisition of Mural Oncology plc on December 5, 2025, via an Irish High Court–sanctioned scheme of arrangement. Under the transaction agreement, Mural shareholders are entitled to receive a cash price of $2.035 per share. Outstanding Mural stock options were canceled at closing and converted into the right to receive cash equal to the per‑share consideration minus the option exercise price, while options with exercise prices at or above $2.035 received no payment. Outstanding restricted stock units were canceled and converted into the right to receive cash equal to the $2.035 per‑share consideration. XOMA plans to file audited Mural financial statements and unaudited pro forma combined financial information for XOMA and Mural in a later amendment.